Pediatrix Medical Group (NYSE:MD) Downgraded to “Buy” Rating by Wall Street Zen

Pediatrix Medical Group (NYSE:MD) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

MD has been the subject of a number of other research reports. UBS Group upped their price objective on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a “neutral” rating in a research note on Thursday, August 14th. Zacks Research raised Pediatrix Medical Group to a “strong-buy” rating in a research note on Monday, August 11th. Finally, Leerink Partners increased their price target on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a research note on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Pediatrix Medical Group presently has an average rating of “Moderate Buy” and an average target price of $16.79.

Pediatrix Medical Group Stock Performance

Shares of MD opened at $16.67 on Friday. The company has a quick ratio of 1.80, a current ratio of 1.80 and a debt-to-equity ratio of 0.70. The business has a 50-day simple moving average of $14.75 and a two-hundred day simple moving average of $14.18. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 12.92 and a beta of 1.30. Pediatrix Medical Group has a 52 week low of $10.39 and a 52 week high of $17.67.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.11. The firm had revenue of $468.84 million during the quarter, compared to analyst estimates of $464.37 million. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The business’s quarterly revenue was down 7.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.34 earnings per share. On average, analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current year.

Institutional Investors Weigh In On Pediatrix Medical Group

Several institutional investors have recently modified their holdings of MD. Northern Trust Corp lifted its stake in shares of Pediatrix Medical Group by 18.0% in the 4th quarter. Northern Trust Corp now owns 966,347 shares of the company’s stock valued at $12,678,000 after purchasing an additional 147,522 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Pediatrix Medical Group by 87.8% in the 4th quarter. BNP Paribas Financial Markets now owns 34,776 shares of the company’s stock valued at $456,000 after purchasing an additional 16,256 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Pediatrix Medical Group by 53.1% in the 4th quarter. Deutsche Bank AG now owns 74,023 shares of the company’s stock valued at $971,000 after purchasing an additional 25,663 shares during the last quarter. Gotham Asset Management LLC lifted its stake in shares of Pediatrix Medical Group by 38.0% in the 4th quarter. Gotham Asset Management LLC now owns 54,642 shares of the company’s stock valued at $717,000 after purchasing an additional 15,044 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Pediatrix Medical Group by 6.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,002 shares of the company’s stock valued at $643,000 after purchasing an additional 2,801 shares during the last quarter. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.